

DOCON TECHNOLOGIES PRIVATE LIMITED

September 24, 2025

To, National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051	To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001
To, Thyrocare Technologies Limited D37/3, TTC MIDC, Turbhe, Navi Mumbai – 400 073.	

Sub: Release of Pledge on Shares of Thyrocare Technologies Limited ("Thyrocare").

Ref: Disclosures pursuant to Regulations 31(2) and Regulation 31(3) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI SAST")

Dear Sir/ Madam,

This is with reference to our earlier disclosure dated September 18, 2025, in respect of release of pledge on **3,76,56,092 equity shares of Thyrocare**, held by Docon Technologies Private Limited ("Docon"), Promoter of Thyrocare, which were pledged with **Vistra ITCL (India) Limited**, Debenture Trustee, for the secured, unlisted, redeemable non-convertible debentures issued by API Holdings Limited.


Pursuant to the redemption of such non-convertible debentures having a total outstanding redemption value aggregating to **INR 1,820 crore**, of which the current outstanding nominal value was **INR 1,545.38 crore**, the pledge created in favour of **Vistra ITCL (India) Limited** (as Debenture Trustee for the below investors) has been released. The investors under the debenture issuance were:

1. Goldman Sachs India AIF Scheme I
2. Goldman Sachs India Alternative Investment Trust AIF Scheme II
3. EvolutionX Debt Capital Master Fund I PTE Limited

Accordingly, please find enclosed the updated disclosure under Regulation 31(2) and 31(3) of SEBI SAST.

You are requested to kindly take the updated disclosure on record.

For and on behalf of
Docon Technologies Private Limited


Madhuri Sudhir Sarangdar
Company Secretary



DOCON TECHNOLOGIES PRIVATE LIMITED

Annexure

Disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company(TC)					Thyrocare Technologies Limited								
Names of the stock exchanges where the shares of the target company are listed					1. BSE Limited 2. National Stock Exchange of India Limited								
Date of reporting					Originally reported on September 18, 2025, and revised reporting on September 24, 2025								
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked					Promoter: Docon Technologies Private Limited PAC: API Holdings Limited								
Details of the creation of encumbrance													
Name of the promoter(s) or PACs with him	Promoter holding in the target company (1)		Promoter holding already encumbered (2)		Details of events pertaining to encumbrance (3)							Post event holding of Encumbered shares {creation [(2)+(3)] / release [(2)-(3)] / invocation [(1)-(3)]}	
	Number	% of total share capital	Number	% of total share capital	Type of event (creation / Release / invocation)	Date of creation / release / invocation of encumbrance	Type of encumbrance (pledge/ line/ non disposal undertaking/ others)	Reasons for encumbrance **	Number	% of share capital	Name of the entity in whose favor shares Encumbered ***	Number	% of total share capital
Docon Technologies Private Limited	3,76,56,092	71.06	3,76,56,092	71.06	Release of Pledge shares API Holdings Limited ("the Holding Company") had earlier issued secured, unlisted, redeemable non-convertible debentures with a total outstanding redemption value	September, 16, 2025	Release of Pledge shares	Release of Pledge shares API Holdings Limited ("the Holding Company") had earlier issued secured, unlisted, redeemable non-convertible	3,76,56,092	71.06	The shares were pledged in favour of Vistra ITCL (India) Limited, as Debenture Trustee for the non-convertible debentures issued by API Holdings Limited, having a total outstanding redemption value aggregating to INR 1,820 crore, of which the outstanding nominal value was INR	Nil	Nil

DOCON TECHNOLOGIES PRIVATE LIMITED

					aggregating to INR 1,820 crore, of which the outstanding nominal value was INR 1,545.38 crore. The said debentures have now been redeemed, and accordingly, the pledge on Thyrocare shares has been released.				debentures with a total outstanding redemption value aggregating to INR 1,820 crore, of which the outstanding nominal value was INR 1,545.38 crore. The said debentures have now been redeemed, and accordingly, the pledge on Thyrocare shares has been released.				1,545.38 crore. The said pledge has now been released. The investors under the debenture issuance were: 1) Goldman Sachs India AIF Scheme I – nominal value of INR 94.11 crore 2) Goldman Sachs India Alternative Investment Trust AIF Scheme II – nominal value of INR 1,187.27 crore 3) EvolutionX Debt Capital Master Fund PTE Limited – nominal value of INR 264.00 crore		
--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	--

For and on behalf of Docon Technologies Private Limited

Madhuri

Madhuri Sudhir Sarangdhar
Company Secretary

